ALK-positive histiocytosis is a rare histiocytic proliferative disorder most often seen in infants and young children. 1,2 We describe a patient with a novel presentation of this condition characterized by a palatal mass that was responsive to treatment with first-generation ALK inhibitor, crizotinib. The unique immunophenotypic and molecular characteristics of ALK-positive histiocytosis provide an opportunity for targeted therapy with ALK inhibitors and additional research should be focused on further characterization of this condition and potential treatment options. Additionally, we support the suggestion that ALK-positive histiocytosis should be considered a distinct entity from other histiocytic proliferative disorders 1,2, such as Langerhans cell histiocytosis.
Dolan, Ella and Katie Harmoney. "A Rare Presentation of Pediatric ALK-positive Histiocytosis as Palatal Mass with Response to ALK Inhibitor Crizotinib Treatment: Case report." (2022). https://digitalrepository.unm.edu/hsc_2022_pediatric_research/3